Yahoo Finance Allscripts' Veradigm Business Line Unveils New Solution
Allscripts Healthcare Solutions, Inc.’s MDRX Veradigm business line has recently introduced an exclusive new software solution for specialty medication management. The new solution — AccelRx — has been created to simplify specialty medication fulfillment and lower patient waiting times.
Notably, the new solution is likely to boost Allscript’s Veradigm business segment, which is committed toward streamlining the complex healthcare system with next-generation healthcare solutions. These solutions, as a result, improve quality, efficacy and value of healthcare.
Few Words About AccelRx
The new solution has been created to streamline the requirements necessary to distribute the growing number of specialty medications that are being prescribed. The solution leverages broad industry partnerships that have been built over decades of e-prescribing and previous authorization leadership that helps providers to cut down time on phone calls and faxes. This, in turn, will drive increasing medication adherence and improve patient care.
Benefits of the Solution
Healthcare providers are likely to benefit from this solution as it will help them in the reduction of time that takes to deliver the medications to patients.
With the growing importance of specialty medications and the impact that they have on healthcare in the United States, the number of patients and providers gaining from the value of AccelRx continues to grow as well. Thus, Allscript’s Veradigm business unit is focused in the development of ongoing partnerships with key industry stakeholders that will enable the expansion of the scope of enhancement of the AccelRx solution throughout 2020 and further.
Specialty medications represents 3% of all prescriptions written in the United States, in spite of that these medications are estimated to account for up to 50% of the total sped on prescription medications in 2020.
Market Prospects
Per a report by ResearchandMarkets, the global specialty drug distribution market is estimated to grow from $1.29 billion in 2018 to $2.91 billion by end of 2025 at a CAGR of 12.3%. Therefore, it is important to note here that the introduction of the AccelRx solution is well-timed.
Some other key players in the medical products space are Stryker Corporation SYK, Haemonetics Corporation HAE and NuVasive, Inc. NUVA.
Stryker is one of the world’s largest medical device companies operating in the orthopedic market. The company has three business segments: Orthopaedics, MedSurg, and Neurotechnology & Spine.
Haemonetics Corporation provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally.
NuVasive is one of the leading global medical device companies in the spine market, focused on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stryker Corporation (SYK) : Free Stock Analysis Report
Allscripts Healthcare Solutions, Inc. (MDRX) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
NuVasive, Inc. (NUVA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
